<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749424</url>
  </required_header>
  <id_info>
    <org_study_id>CRDIT 00-01/03</org_study_id>
    <nct_id>NCT00749424</nct_id>
  </id_info>
  <brief_title>The Study of the Crushing Technique Application Using SES in Coronary Bifurcations.</brief_title>
  <acronym>CACTUS</acronym>
  <official_title>CORONARY BIFURCATIONS: APPLICATION OF THE CRUSHING TECHNIQUE USING SIROLIMUS-ELUTING STENTS - The &quot;CACTUS&quot; Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and effectiveness of two different&#xD;
      approaches to treat bifurcational lesions with CYPHER SELECT™ Sirolimus-eluting&#xD;
      Balloon-expandable Coronary Stent , Cordis Corp): a) the &quot;crushing&quot; technique to stent both&#xD;
      branches vs. b) a provisional T stenting technique of the side branch.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized study that will be conducted at up to 5 centers in Italy.&#xD;
      All patients who meet the eligibility criteria will be treated with the Cypher SelectTM Stent&#xD;
      and Stent Delivery System (SDS). Patients will have repeat angiography at six months, with&#xD;
      clinical follow-up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse and Cardiac Events (MACE)</measure>
    <time_frame>6 and 12 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal lumen diameter (MLD)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent diameter stenosis (%DS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>crushing technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>provisional T stenting technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SES</intervention_name>
    <description>CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SES</intervention_name>
    <description>CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is a male or non-pregnant female patient &gt;= 18 years of age [NOTE: Females of&#xD;
             child-bearing potential must have a negative pregnancy test];&#xD;
&#xD;
          2. Has a diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B&amp;C, I-II) OR has documented silent ischemia;&#xD;
&#xD;
          3. Has at least TIMI I coronary flow in both the main and side branches;&#xD;
&#xD;
          4. Involves a single treatment of a de novo bifurcation lesion in native coronary&#xD;
             arteries of patients with single or multivessel disease; patients with multiple&#xD;
             lesions can be included only if other lesions treated during the index procedure are&#xD;
             successfully treated prior to the treatment of the bifurcation lesion;&#xD;
&#xD;
          5. Has a true bifurcation lesion defined as stenosis &gt; 50% in both the main branch and&#xD;
             the ostium of the side branch;&#xD;
&#xD;
          6. Has a maximum treatable main or side branch lesion length &lt;=28 mm;&#xD;
&#xD;
          7. Has a main branch vessel that is &gt;= 2.5 mm and &lt;= 3.5 mm in diameter by on-line QCA&#xD;
             proximal to the bifurcation;&#xD;
&#xD;
          8. Has a side branch vessel that is &gt;= 2.25 mm and &lt;= 3.5 mm in diameter by on-line QCA;&#xD;
&#xD;
          9. Is an acceptable candidate for coronary artery bypass surgery (CABG);&#xD;
&#xD;
         10. Is willing to comply with the specified follow-up evaluation;&#xD;
&#xD;
         11. The patient or legally authorized representative must provide written informed consent&#xD;
             prior to the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented&#xD;
             elevation of CK levels &gt; 2 times normal or CK-MB levels &gt; 3 times normal within the&#xD;
             preceding 24 hours and/or the CK and CK-MB enzymes remain above normal at the time of&#xD;
             treatment;&#xD;
&#xD;
          2. Has unstable angina classified as Braunwald A I-III, B&amp;C III;&#xD;
&#xD;
          3. Has a bifurcation lesion in a non protected left main;&#xD;
&#xD;
          4. Has an ejection fraction &lt;= 35%;&#xD;
&#xD;
          5. Has known allergies to the following: aspirin, clopidogrel bisulfate (Plavix) and&#xD;
             ticlopidine (Ticlid), heparin, or sirolimus;&#xD;
&#xD;
          6. Has a known serious allergy to contrast media or stainless steel that cannot be&#xD;
             managed medically;&#xD;
&#xD;
          7. Has impaired renal function (creatinine &gt; 3.0 mg/dl);&#xD;
&#xD;
          8. There is presence of thrombus in the bifurcation lesion;&#xD;
&#xD;
          9. Has a target lesion with excessive tortuousity unsuitable for stent delivery and&#xD;
             deployment;&#xD;
&#xD;
         10. Has a totally occluded vessel;&#xD;
&#xD;
         11. Is the recipient of a heart transplant;&#xD;
&#xD;
         12. Has a significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study;&#xD;
&#xD;
         13. Is currently participating in an investigational drug or another device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Colombo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Centro San Raffaele del Monte Tabor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Colombo A, Bramucci E, Saccà S, Violini R, Lettieri C, Zanini R, Sheiban I, Paloscia L, Grube E, Schofer J, Bolognese L, Orlandi M, Niccoli G, Latib A, Airoldi F. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation. 2009 Jan 6;119(1):71-8. doi: 10.1161/CIRCULATIONAHA.108.808402. Epub 2008 Dec 22.</citation>
    <PMID>19103990</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hans-Peter Stoll, MD</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

